Loading clinical trials...

The MIRIA Acne Scar Study | Clinical Trials | Clareo Health

ACTIVE_NOT_RECRUITINGNA

The MIRIA Acne Scar Study

NCT05597267•AVAVA, Inc.

Summary

This study is being conducted to evaluate the performance and efficacy of the AVAVA MIRIA Laser Skin System treatment on acne scars. Participants will be treated with the MIRIA laser at least 4 times with each treatment spaced 4-6 weeks apart. The improvement of acne scars will be evaluated at 1 month and 3 months with a possibility of 6 months evaluation after the fourth treatment.

Eligibility

Age

18 - 65 years

Sex

ALL

Healthy Volunteers

Yes

Inclusion Criteria

•Subjects 18-65 years of age
•Acne scars on the face
•Able and willing to comply with all study procedures and at home care; and,
•Able and willing to give informed consent.

Exclusion Criteria

•Hypersensitive to light in the near infrared wavelength region
•On medication known to increase sensitivity to sunlight
•Seizure disorder triggered by light
•Takes or has taken oral isotretinoin, such as Accutane®, within the last six months
•Use of topical over the counter or prescription retinoids such as Retinol creams, gels, Tazarotene, Tretinoin, Adapalene, within the last 30 days
•Active acne or rosacea
•Active localized or systemic infection, or an open wound or abscess in area being treated
•Significant systemic inflammatory disease or illness, such as lupus, or an illness localized in area being treated
•Common acquired nevi that are predisposed to the development of malignant melanoma
•Current or prior herpes simplex in the target treatment area
+20 more criteria

Locations (3)

Enchantress Dermatology

Miami, Florida, United States

AVAVA, Inc.

Waltham, Massachusetts, United States

Laser and Skin Surgery Center of New York

New York, New York, United States

Key Dates

Start Date

November 4, 2022

Primary Completion Date

February 28, 2025

Completion Date

February 28, 2025

Last Updated

March 7, 2025

Enrollment

ESTIMATED participants

Conditions

Acne Scars - Mixed Atrophic and Hypertrophic

Interventions

MIRIA Laser

DEVICE

Clinical Evaluation of the Safety and Performance of FRF for the Treatment and Reduction of Acne Scarring

NCT04827680

Acne Scars - Mixed Atrophic and Hypertrophic

View study

COMPLETEDNA

Tripeptide/Hexapeptide Topical and Hybrid Laser Treatment for Acne Scarring

NCT04606134

Acne Scars - Mixed Atrophic and Hypertrophic

View study

UNKNOWNNA

Microneedling With Topical Preparations in the Treatment of Atrophic Post-acne Scars

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: March 7, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

The MIRIA Acne Scar Study

Inclusion Criteria

Exclusion Criteria

Clinical Evaluation of the Safety and Performance of FRF for the Treatment and Reduction of Acne Scarring

Tripeptide/Hexapeptide Topical and Hybrid Laser Treatment for Acne Scarring

Microneedling With Topical Preparations in the Treatment of Atrophic Post-acne Scars

Performance of PicoWayTM Picosecond Fractional Laser for Acne Scars